Hereditary Angioedema
NHS England
This tender has closed
The submission deadline for this contract has passed. There may be more active goods tenders from NHS England, and hundreds more across the UK public sector.
Key details
Procurement
- 33600000 Pharmaceutical products
- 33141520 Plasma extracts
- 33141510 Blood products
What happened
NHS England awarded this contract to Martindale Pharma | Piramal Critical care Limited | CSL Behring UK Ltd | Wockhardt UK Limited | Cipla | Takeda UK Ltd | BioCryst Ireland Limited | Pharming Group | Accord-UK Ltd | Celix Pharma Ltd. worth £74,500,000 on 20 Jun 2022. The contract runs until 31 Dec 2023.
Description
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Awarded suppliers (10)
- Martindale Pharma
- Piramal Critical care Limited
- CSL Behring UK Ltd
- Wockhardt UK Limited
- Cipla
- Takeda UK Ltd
- BioCryst Ireland Limited
- Pharming Group
- Accord-UK Ltd
- Celix Pharma Ltd.
Contact
Identifiers
Explore related tenders
Other tenders from NHS England
View all →External ID: cf-ocds-b5fd17-5242c430-9651-453d-9ccd-71a66de32b6f • Added 5 October 2026